We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Topical Cyclosporine 0.05% in the Prevention of Ocular Surface Inflammation Secondary to Pterygia

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00383396
First Posted: October 3, 2006
Last Update Posted: February 13, 2007
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Innovative Medical
  Purpose
To Determine if topical cyclosporine 0.05% BID prevents recurrent inflammation and improves comfort in eyes with pterygia.

Condition Intervention Phase
Pterygia Drug: Topical Cyclosporine Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)

Resource links provided by NLM:


Further study details as provided by Innovative Medical:

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Criteria

Inclusion Criteria:

  • pts with symptomatic pterygia unresponsive to palliative treatment.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00383396


Locations
United States, Florida
Dr. Schechter
Boynton Beach, Florida, United States, 33426
Sponsors and Collaborators
Innovative Medical
Investigators
Principal Investigator: Barry Schechter, MD Florida Eye Microsurgical Institute
  More Information

ClinicalTrials.gov Identifier: NCT00383396     History of Changes
Other Study ID Numbers: 1963
First Submitted: September 29, 2006
First Posted: October 3, 2006
Last Update Posted: February 13, 2007
Last Verified: February 2007

Additional relevant MeSH terms:
Pterygium
Conjunctival Diseases
Eye Diseases
Cyclosporins
Cyclosporine
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors